18.56

4.09% 0.73

Pre-market: 18.45 -0.11 -0.59%

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $18.56, with a volume of 12.57M. It is up +4.09% in the last 24 hours and up +30.98% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Previous Close:

$17.83

Open:

$17.62

24h Volume:

12.57M

Relative Volume:

3.09

Market Cap:

$4.04B

Revenue:

$10.68M

Net Income/Loss:

$-272.71M

P/E Ratio:

-11.86

EPS:

-1.565

Net Cash Flow:

$-213.38M

1W Performance:

+16.88%

1M Performance:

+30.98%

6M Performance:

+116.82%

1Y Performance:

+459.04%

1-Day Range:

$17.62

$18.75

1-Week Range:

$16.14

$18.94

52-Week Range:

$3.025

$18.94

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1095)

Industry

Biotechnology (615)

Phone

617-370-8837

Address

60 HAMPSHIRE STREET, CAMBRIDGE

Employee

192

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	18.56	4.04B	10.68M	-272.71M	-213.38M	-1.565
VRTX Vertex Pharmaceuticals Inc	491.34	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.18	55.17B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.37	38.90B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	38.71B	742.00K	-1.37B	-1.07B	-7.0731

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-26	Upgrade	Oppenheimer	Perform → Outperform
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-04-25	Resumed	Guggenheim	Buy
Apr-17-25	Initiated	Wells Fargo	Equal Weight
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

Jun 27, 2026

Why Is RLAY Stock Rising Today? - Stocktwits

Jun 27, 2026

RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib - MSN

Jun 27, 2026

Jun 26, 2026

Relay Therapeutics (RLAY) Short Interest & Short Float | Updated Jun 2026 $RLAY - MarketBeat

Jun 25, 2026

Relay Therapeutics (RLAY) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España

Jun 25, 2026

Jun 24, 2026

Form 4 Relay Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria

Jun 24, 2026

Relay Therapeutics president R&D sells $1.58m in stock By Investing.com - Investing.com Nigeria

Jun 24, 2026

Relay Therapeutics president R&D sells $1.58m in stock - Investing.com

Jun 24, 2026

Relay Therapeutics (RLAY) R&D chief exercises options and sells 93K shares - Stock Titan

Jun 24, 2026

Relay Therapeutics (NASDAQ: RLAY) CFO sells 187,163 shares after exercising options - Stock Titan

Jun 24, 2026

8-Day Rally Sends Relay Therapeutics Stock Up 29% - Trefis

Jun 24, 2026

Jun 23, 2026

Relay Therapeutics stock hits 52-week high at 17.54 USD - Investing.com UK

Jun 23, 2026

Relay Therapeutics stock hits 52-week high at 17.54 USD By Investing.com - Investing.com South Africa

Jun 23, 2026

Form 144 RELAY THERAPEUTICS For: 22 June By Investing.com - Investing.com Australia

Jun 23, 2026

Jun 22, 2026

Form 144 | Relay Therapeutics(RLAY.US) Officer Proposes to Sell 3.25 Million in Common Stocks - Moomoo

Jun 22, 2026

Donald A. (RLAY) files Form 144 to sell 93,456 shares on 06/22/2026 - Stock Titan

Jun 22, 2026

RLAY: Director Thomas Catinazzo executed 4 10b5-1 sales (Apr–May 2026) - Stock Titan

Jun 22, 2026

Jun 20, 2026

Relay Therapeutics StockAnalyst views and long-term strategy in focus - Ad-hoc-news.de

Jun 20, 2026

Jun 19, 2026

Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Relay Therapeutics (RLAY) - The Globe and Mail

Jun 19, 2026

Jun 18, 2026

Top Smidcap Pick: TD Cowen Highlights Relay Therapeutics By Investing.com - Investing.com South Africa

Jun 18, 2026